International Stem Cell Corporation (OTCBB:ISCO) has issued a message
from Chairman Kenneth C. Aldrich containing a recap of company
milestones achieved since the company completed its Share Exchange
Agreement on December 29, 2006.
A full text of the Chairman's Message has been
posted on the company's website: www.internationalstemcell.com ABOUT INTERNATIONAL STEM CELL CORPORATION:
International Stem Cell is a biotechnology company currently focused on
developing therapeutic and research products. In the area of therapeutic
product development, ISCO's objective is to create an unlimited source
of human cells for use in the treatment of several diseases, including
diabetes, liver disease and retinal disease through cell transplant
therapy. In furtherance of this objective, ISCO is currently developing
human stem cells, techniques to cause those stem cells to be
"differentiated" into the specific cell types required for transplant,
and manufacturing protocols to produce the cells without contamination
with animal by-products, a characteristic likely to be important in
meeting U.S. Food and Drug Administration requirements. ISCO through its
subsidiary, Lifeline Cell Technology, produces and markets a line of
products for research that includes serum-free growth media and reagents
essential to the process of creating and differentiating stem cells into
therapeutic products needed for therapeutic cell transplantation
research to academic and commercial researchers in related fields.
To receive ongoing public information about the company, please click on
the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0 Forward-Looking Statements
This news release and the "Message from the Chairman" letter on the
company's website to which it refers, may contain statements pertaining
to future financial and/or operating results, future growth in research,
technology, clinical development and potential opportunities for the
company and its subsidiary, along with other statements about the future
expectations, beliefs, plans, goals, or prospects expressed by
management. Those and any statements that are not historical fact
(including, but not limited to statements that contain words such as "will,""believes,""plans,""anticipates,""expects,""estimates,")
should be considered forward-looking statements. Forward-looking
statements involve risks and uncertainties, including, without
limitation, risks inherent in the development and/or commercialization
of potential products, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital, and
maintenance of intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many
uncertainties that affect the company's business, particularly those
mentioned in the cautionary statements found in the company's Securities
and Exchange Commission filings. The company disclaims any intent or
obligation to update these forward-looking statements.
|